Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Inozyme Pharma (INZY)
NASDAQ:INZY
Inozyme Pharma (INZY) Stock Price & Analysis
280 Followers
INZY Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$2.69 - $7.80
Previous Close$4.74
Volume327.05K
Average Volume (3M)683.75K
Market Cap
$292.80M
Enterprise Value$150.80M
Total Cash (Recent Filing)$188.59M
Total Debt (Recent Filing)$46.59M
Price to Earnings (P/E)-3.4
Beta1.18
Next Earnings
May 07, 2024EPS Estimate
-$0.36Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.39
Shares Outstanding61,771,977
10 Day Avg. Volume579,676
30 Day Avg. Volume683,745
Standard Deviation0.32
R-Squared0.06
Alpha-0.01
Financial Highlights & Ratios
Price to Book (P/B)2.04
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-3.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-1.96
Forecast
1Y Price Target
$17.00Price Target Upside258.65% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Inozyme Pharma News
Ownership Overview
55.16% Insiders
14.01% Mutual Funds
7.45% Other Institutional Investors
23.38% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
INZY FAQ
What was Inozyme Pharma’s price range in the past 12 months?
Inozyme Pharma lowest stock price was $2.69 and its highest was $7.79 in the past 12 months.
What is Inozyme Pharma’s market cap?
Currently, no data Available
When is Inozyme Pharma’s upcoming earnings report date?
Inozyme Pharma’s upcoming earnings report date is May 07, 2024 which is yesterday.
How were Inozyme Pharma’s earnings last quarter?
Inozyme Pharma released its earnings results on Mar 12, 2024. The company reported -$0.33 earnings per share for the quarter, missing the consensus estimate of -$0.319 by -$0.011.
Is Inozyme Pharma overvalued?
According to Wall Street analysts Inozyme Pharma’s price is currently Undervalued.
Does Inozyme Pharma pay dividends?
Inozyme Pharma does not currently pay dividends.
What is Inozyme Pharma’s EPS estimate?
Inozyme Pharma’s EPS estimate is -$0.36.
How many shares outstanding does Inozyme Pharma have?
Inozyme Pharma has 61,771,976 shares outstanding.
What happened to Inozyme Pharma’s price movement after its last earnings report?
Inozyme Pharma reported an EPS of -$0.33 in its last earnings report, missing expectations of -$0.319. Following the earnings report the stock price went down -0.348%.
Which hedge fund is a major shareholder of Inozyme Pharma?
Among the largest hedge funds holding Inozyme Pharma’s share is Woodline Partners LP. It holds Inozyme Pharma’s shares valued at 1M.
---
Inozyme Pharma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$17.00 (258.65% Upside)
$17.00 (258.65% Upside)
Blogger Sentiment
Bullish
INZY Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 300.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $52.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.3%
Last 30 Days ▼ 5.0%
Last 30 Days ▼ 5.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-18.55%
12-Months-Change
Fundamentals
Return on Equity
-54.98%
Trailing 12-Months
Asset Growth
44.29%
Trailing 12-Months
Company Description
Inozyme Pharma
Inozyme Pharma Inc is a rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases of abnormal mineralization impacting the vasculature, soft tissue and skeleton. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies. Its product candidate, INZ-701, is a soluble, recombinant, or genetically engineered, fusion protein that is designed to correct a defect in the mineralization pathway caused by ENPP1 and ABCC6 deficiencies.
---
INZY Stock 12 Months Forecast
Average Price Target
$17.00
▲(258.65% Upside)
Technical Analysis
Best Analysts Covering INZY
1 Year
1 Year Success Rate
7/11 ratings generated profit
1 Year Average Return
+26.54%
assigned a buy rating 28 days ago
Copying Joseph Stringer's trades and holding each position for 1 Year would result in 63.64% of your transactions generating a profit, with an average return of +26.54% per trade.
---